A £279m partnership in the UK Government’s life sciences sector

The UK government recently announced a £279 million investment in its life sciences sector through a partnership with Lilly, a multinational pharmaceutical company. This significant investment is aimed at accelerating healthcare innovation and advancing new care delivery models, particularly focused on improving health for people living with obesity.

The Health and Social Care Secretary remarked that “partnerships like these are key to building a healthier society,” underscoring the mutual benefits that collaboration contracts can bring to both public health initiatives and business development in life sciences.

This partnership reaffirms the UK’s status as a global leader in life sciences by enabling transformative research within early-stage R&D businesses. Through this collaboration, the NHS gains broader access to research and development across the UK, unlocking the potential for revolutionary treatments.

However, navigating the complex landscape of life sciences investment poses significant challenges. With thousands of groundbreaking research projects competing for limited resources, R&D labs often struggle to secure funding, particularly as public funds become less available. This gap between public and private funding is referred to as the “Valley of Death,” where many promising research projects lose crucial support and miss opportunities to advance.

Addressing the ‘Valley of Death’ in Life Sciences R&D Funding

Overcoming the Valley of Death is crucial for the longevity of R&D projects, as it allows groundbreaking research to move from initial stages to impactful, scalable solutions. Many life sciences projects require substantial private funding to bridge this gap, and collaboration contracts are essential for ensuring financial support and long-term viability.

A collaboration contract outlines the shared goals, roles, and benefits between research entities and investors, providing clarity and direction throughout the project. These contracts allow for pooling resources, skills, and perspectives, often accelerating research progress and generating valuable intellectual property. R&D companies seeking funding and strategic partnerships often use collaboration contracts to gain access to essential expertise and financial resources.

Collaboration contracts provide 4 key things:

1. What the collaboration is about
2. How the parties will work together
3. How the benefits of the collaboration will be shared
4. The roles and responsibilities of the parties involved.

A key area for companies entering contractual ventures to consider concerns the generation of intellectual property and the allocation of rights between the parties involved. It is advised the agreement is drafted and/or reviewed by a legal professional to ensure clarity throughout the contract.

Contact Berry Smith for Expert Collaboration Contract Services

At Berry Smith, we are experts in collaboration, and we have fostered many long-term relationships between researchers and investors. We provide a bespoke collaboration contract drafting service, tailored to prioritise your R&D requirements.

For more information on collaboration contracts or to schedule a consultation, please do not hesitate to reach out to us:

Email: commercial@berrysmith.com

Phone: 02920 345511

For more insights check out our news here
Follow us on Linkedin!